Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S.

  Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S.

- First FDA Cleared Blood Glucose Meter that Connects Directly to iPhone® and
iPod touch® -

- Available at Apple® Retail Stores and Walgreens Nationwide, Online at
Apple.com, Walgreens.com and through Diabetic Care Services -

- Recipient of Two Design Awards for Outstanding Product Design -

PR Newswire

BRIDGEWATER, N.J., May 2, 2012

BRIDGEWATER, N.J., May 2, 2012 /PRNewswire/ --Sanofi US announced today that
the iBGStar® Blood Glucose Monitoring System, consisting of the iBGStar® blood
glucose meter and iBGStar® Diabetes Manager App,is commercially available in
the U.S.iBGStar® is the first Food and Drug Administration (FDA) cleared
blood glucose meter that directly connects to the iPhone® and iPod touch®,
offering accurate blood glucose monitoring that seamlessly integrates into the
lives of people with diabetes. iBGStar®is available for purchase at Apple®
Retail Stores and all Walgreens stores nationwide, online at Apple.com,
Walgreens.com andthrough Diabetic Care Services.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/46108-sanofi-ibgstar-blood-glucose-monitoring-system

"Many people with diabetes today rely both on their iPhone® or iPod touch® and
blood glucose monitors as important parts of their daily lives," said Naina
Sinha, MD, an in-patient diabetes attending physician and assistant professor
of medicine at a leading academic medical center and university in New York
City. "By combining these two essential tools, iBGStar® makes it possible to
provide blood glucose tracking, monitoring and reporting together in a new
way."

About iBGStar®
When iBGStar® is directly connected to an iPhone® or iPod touch® and used with
the iBGStar® Diabetes Manager App, blood glucose results are presented on the
Multi-Touch display quickly after monitoring.

iBGStar® can also be used independently to measure blood glucose levels;
results can be synchronized later to an iPhone® or iPod touch®. iBGStar® and
BGStar® Blood Glucose Test Strips, which are used with iBGStar®, are available
at all Walgreens stores nationwide and online at Walgreens.com and through
Diabetic Care Services. These test strips may be covered under certain health
insurance plans so individuals should check directly with their provider.

The iBGStar® Diabetes Manager App has a range of features and multiple views
for analyzing glucose patterns on-the-go. Visual graphs and statistics can
help people record and track their readings, carbohydrate intake, insulin
doses (if taking insulin) and more. Color-coded scorecards show individual
monitoring results for easy identification of high or low blood glucose
levels. A 'share' function allows specific data to be sent via e-mail to
caregivers and/or healthcare teams. The iBGStar® Diabetes Manager App is
available for free from the App Store on iPhone® and iPod touch® or at
www.itunes.com/appstore.

"Sanofi is pleased to launch iBGStar®, which expands our diabetes portfolio as
we pursue comprehensive disease management offerings and further illustrates
our commitment to developing innovative solutions that help improve the lives
of people with diabetes," commented  Dennis Urbaniak, Vice President, Head of
U.S. Diabetes, Sanofi US. "The iBGStar® Blood Glucose Monitoring System will
help people living with diabetes check their blood sugar and communicate with
their healthcare teams, using mobile technologies that have become central to
so many people's lives."

In March 2010, Sanofi and AgaMatrix signed an agreement for the development,
supply and commercialization of Blood Glucose Monitoring solutions. iBGStar®
is a result of this agreement.

iBGStar® received the Good Design™ Award in 2011 for outstanding product
design in the medical category from the Chicago Athenaeum of Architecture and
Design and the European Centre for Architecture Art Design and Urban Studies.
Additionally, iBGStar® received the red dot design award in 2011 for
outstanding product design in the life science and medicine category. The red
dot design award is one of the most renowned international design competitions
(www.red-dot.de/presse), with almost 14,000 entries from 68 countries in 2010
alone. Winners are considered to be the best design in the industry
worldwide.

Apple®, iPhone® and iPod touch® are trademarks of Apple Inc, registered in the
U.S. and other countries. App Store is a service mark of Apple Inc. Content
purchased from the iTunes Store is for personal lawful use only. Don't steal
music.

For more information, visit www.ibgstar.us.

About the Sanofi Diabetes Division
Sanofi strives to help people manage the complex challenges of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insight that comes from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services, and devices, including innovative blood glucose
monitoring systems. Sanofi markets both injectable and oral medications for
people with type 1 or type 2 diabetes. Investigational compounds in the
pipeline include an injectable GLP-1 agonist being studied as a single agent,
in combination with basal insulin, and/or in combination with oral
antidiabetic agents.

Important Information
The iBGStar^® meter and lancing device are for single patient use. Do not
share them with anyone including other family members. Do not use on multiple
patients. All parts of the kit are considered biohazardous and can potentially
transmit infectious diseases, even after you have performed cleaning and
disinfection.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US, also referred to as sanofi-aventis
U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us
or call 1-800-981-2491.

Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

US.BGM.12.02.076



SOURCE Sanofi US
 
Press spacebar to pause and continue. Press esc to stop.